REFERENCES
BAI, Z., SHEN, G. & DONG, L. 2021. Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy. Int J Rheum Dis, 24,815-827.
CHEN, Z., WANG, X. & YE, S. 2019. Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. N Engl J Med, 381, 291-293.
DIDONA, D., JURATLI, H. A., SCARSELLA, L., EMING, R. & HERTL, M. 2020. The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants. Eur J Dermatol,30, 229-242.
DING, Y., HUANG, B., WANG, Y., HOU, J., CHI, Y., ZHOU, Z. & LI, J. 2021. Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis. Ann Rheum Dis, 80,543-545.
KURASAWA, K., ARAI, S., NAMIKI, Y., TANAKA, A., TAKAMURA, Y., OWADA, T., ARIMA, M. & MAEZAWA, R. 2018. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford),57, 2114-2119.
LUNDBERG, I. E., TJäRNLUND, A., BOTTAI, M., WERTH, V. P., PILKINGTON, C., DE VISSER, M., ALFREDSSON, L., AMATO, A. A., BAROHN, R. J., LIANG, M. H., SINGH, J. A., AGGARWAL, R., ARNARDOTTIR, S., CHINOY, H., COOPER, R. G., DANKó, K., DIMACHKIE, M. M., FELDMAN, B. M., GARCIA-DE LA TORRE, I., GORDON, P., HAYASHI, T., KATZ, J. D., KOHSAKA, H., LACHENBRUCH, P. A., LANG, B. A., LI, Y., ODDIS, C. V., OLESINSKA, M., REED, A. M., RUTKOWSKA-SAK, L., SANNER, H., SELVA-O’CALLAGHAN, A., SONG, Y. W., VENCOVSKY, J., YTTERBERG, S. R., MILLER, F. W. & RIDER, L. G. 2017. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol,69, 2271-2282.
MOTEGI, S. I., SEKIGUCHI, A., TOKI, S., KISHI, C., ENDO, Y., YASUDA, M., IKEUCHI, H., SAKAIRI, T., HARA, K., YAMAGUCHI, K., MAENO, T., HIROMURA, K. & ISHIKAWA, O. 2019. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.Eur J Dermatol, 29, 511-517.
PAIK, J. J., CASCIOLA-ROSEN, L., SHIN, J. Y., ALBAYDA, J., TINIAKOU, E., LEUNG, D. G., GUTIERREZ-ALAMILLO, L., PERIN, J., FLOREA, L., ANTONESCU, C., LEUNG, S. G., PURWIN, G., KOENIG, A. & CHRISTOPHER-STINE, L. 2021. Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients. Arthritis Rheumatol, 73, 858-865.
WALDMAN, R., DEWANE, M. E. & LU, J. 2020. Dermatomyositis: Diagnosis and treatment. J Am Acad Dermatol, 82, 283-296.
YAMAOKA, T., DOI, C., YOKOMI, A., TANEMURA, A., MUROTA, H., TANI, M., SARUBAN, H., HAMAGUCHI, Y., FUJIMOTO, M. & KATAYAMA, I. 2014. Anti-MDA5 antibody-positive dermatomyositis with lethal progressive interstitial lung disease and advanced gastric cancer. Eur J Dermatol,24, 490-1.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.